Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7179498 | 0.82 | NR5A1 (0.34) | — | |
| SCHEMBL978478 | 0.69 | SHBG (0.36) | SHBGDRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11134426 | 0.61 | HTR1A (0.38) | HSD17B1SHBGHTR1A | |
| SCHEMBL11228428 | 0.61 | HTR1A (0.38) | HSD17B1SHBGHTR1A | |
| SCHEMBL13725675 | 0.59 | SHBG (0.70) | HSD17B1SHBGHTR2B | |
| SCHEMBL30887214 | 0.59 | SHBG (0.70) | HSD17B1SHBGHTR2B | |
| SCHEMBL29446097 | 0.59 | SHBG (0.70) | HSD17B1SHBGHTR2B | |
| SCHEMBL11096655 | 0.59 | SHBG (0.70) | HSD17B1SHBGHTR2B | |
| SCHEMBL975788 | 0.59 | SHBG (0.70) | HSD17B1SHBGHTR2B | |
| SCHEMBL8038167 | 0.58 | SHBG (0.40) | SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375098-B2 | 8β-vinyl-11β-(ω-substituted)alkyl-estra-1,3,5(10)-trienes | SCHERING A.G. (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1622924-A2 | 8$G(B)-VINYL-11$G(B)-( G(V)-SUBSTITUTED)ALKYL-ESTRA-1,3,5(10)-TRIENES | Schering Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
| US-20050065135-A1 | 8beta-Vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-trienes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| WO-2004094451-A2 | 8$G(B)-VINYL-11$G(B)-($G(V)-SUBSTITUTED)ALKYL-ESTRA-1,3,5(10)-TRIENES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065135-A1 | 8beta-Vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-trienes | CYP19A1, HSD17B11, ESR2 | HSD17B1 14/4885SHBG 12/4885HTR1A 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.